Table 5.

Differences in S100, CD208 and VEGF expression in PCa patients based on PSA levels and different Gleason score

Group	S100 (N)	CD208 (N)	VEGF (N)
A	18.77 ± 4.10 (6)	1.90 ± 0.37 (6)	76.60 ± 3.98 (7)
B	12.57 ± 1.91 (7)c	0.97 ± 0.31 (7)e	83.27 ± 3.24 (9)h
C	9.06 ± 2.43 (9)a,b	0.68 ± 0.10 (8)d	88.38 ± 3.62 (9)f,g
D	18.56 ± 3.81 (5)	1.84 ± 0.57 (5)	76.60 ± 4.16 (6)
E	14.16 ± 4.50 (8)k	1.13 ± 0.42 (8)n	82.40 ± 4.26 (8)q
F	9.33 ± 2.65 (9)i,j	0.68 ± 0.10 (8)l,m	87.78 ± 3.56 (11)o,p

Notes: Group A, PSA < 10 ng/mL; group B, PSA 10–20 ng/mL; group C, PSA > 20 ng/mL; group D, Gleason grade < 7; group E, Gleason grade 7; group F, Gleason grade > 7.

^aP = 0.000 vs group A;

^bP = 0.024 vs group B;

^cP = 0.001 vs group A;

^dP = 0.000 vs group A;

^eP = 0.000 vs group A;

^fP = 0.000 vs group A;

^gP = 0.006 vs group B;

^hP = 0.001 vs group A;

ⁱP = 0.000 vs group D;

^jP = 0.014 vs group E;

^kP = 0.049 vs group D;

^lP = 0.000 vs group D;

^mP = 0.029 vs group E;

ⁿP = 0.004 vs group D;

^oP = 0.000 vs group D;

^pP = 0.007 vs group E;

^qP = 0.012 vs group D. N is the numbers of the cases. Data are presented as mean ± standard deviation.

Abbreviations: PCa, prostate cancer; VEGF, vascular endothelial growth factor; PSA, prostate-specific antigen.